Helen S. Summers
Discovery of new imidazotetrazinones with potential to overcome tumor resistance
Summers, Helen S.; Lewis, William; Williams, Huw E. L.; Bradshaw, Tracey D.; Moody, Christopher J.; Stevens, Malcolm F. G.
Authors
William Lewis
Dr HUW WILLIAMS HUW.WILLIAMS@NOTTINGHAM.AC.UK
SENIOR RESEARCH FELLOW
Dr TRACEY BRADSHAW tracey.bradshaw@nottingham.ac.uk
ASSOCIATE PROFESSOR
Christopher J. Moody
Malcolm F. G. Stevens
Abstract
We describe the design, organic synthesis, and characterization, including X-ray crystallography, of a series of novel analogues of the clinically used antitumor agent temozolomide, together with their in vitro biological evaluation. The work has resulted in the discovery of a new series of anticancer imidazotetrazines that offer the potential to overcome the resistance mounted by tumors against temozolomide. The rationally designed compounds that incorporate a propargyl alkylating moiety and a thiazole ring as isosteric replacement for a carboxamide, are readily synthesized (gram-scale), exhibit defined solid-state structures, and enhanced growth-inhibitory activity against human tumor cell lines, including MGMT-expressing and MMR-deficient lines, molecular features that confer tumor resistance. The cell proliferation data were confirmed by clonogenic cell survival assays, and DNA flow cytometry analysis was undertaken to determine the effects of new analogues on cell cycle progression. Detailed 1H NMR spectroscopic studies showed that the new agents are stable in solution, and confirmed their mechanism of action. The propargyl and thiazole substituents significantly improve potency and physicochemical, drug metabolism and permeability properties, suggesting that the thiazole 13 should be prioritized for further preclinical evaluation.
Citation
Summers, H. S., Lewis, W., Williams, H. E. L., Bradshaw, T. D., Moody, C. J., & Stevens, M. F. G. (2023). Discovery of new imidazotetrazinones with potential to overcome tumor resistance. European Journal of Medicinal Chemistry, 257, Article 115507. https://doi.org/10.1016/j.ejmech.2023.115507
Journal Article Type | Article |
---|---|
Acceptance Date | May 18, 2023 |
Online Publication Date | May 30, 2023 |
Publication Date | Sep 5, 2023 |
Deposit Date | May 22, 2023 |
Publicly Available Date | Jun 7, 2023 |
Journal | European Journal of Medicinal Chemistry |
Print ISSN | 0223-5234 |
Electronic ISSN | 1768-3254 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 257 |
Article Number | 115507 |
DOI | https://doi.org/10.1016/j.ejmech.2023.115507 |
Keywords | Organic Chemistry; Drug Discovery; Pharmacology; General Medicine |
Public URL | https://nottingham-repository.worktribe.com/output/21100715 |
Publisher URL | https://www.sciencedirect.com/science/article/pii/S0223523423004737?via%3Dihub |
Files
Discovery of new imidazotetrazinones with potential to overcome tumor resistance
(3 Mb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by-nc-nd/4.0/
You might also like
Effect of sweeteners and carbonation on aroma partitioning and release in beverage systems
(2022)
Journal Article
Direct routes to functional RAFT agents from substituted N-alkyl maleimides
(2022)
Journal Article
Downloadable Citations
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search